Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
ESMO Open
|
October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
S Morganti, R J Kusmick, M E Hughes, et al.
ESMO Open
|
November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆
A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open
|
August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
A Strahan, Q Jin, A S Raghavendra, et al.
Organic Letters
|
January 13, 2026
Asymmetric Synthesis of KRAS G12C Inhibitor MK-1084 via a Crystallization-Induced Diastereomer Transformation (CIDT)
Hongming Li, Gao Shang, Zhiguo J Song, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A G Waks, O Cohen, B Kochupurakkal, et al.
Journal of Medicinal Chemistry
|
March 23, 2021
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
Ryan V Quiroz, Michael H Reutershan, Sebastian E Schneider, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
A C Garrido-Castro, S E Kim, T Li, et al.
Organic Letters
|
October 30, 2025
Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19
Reed T Larson, Ben W H Turnbull, Patrick J Moon, et al.
Journal of Medicinal Chemistry
|
August 22, 2024
Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat <i>Acinetobacter baumannii</i>: From Screening Impurity to <i>In Vivo</i> Efficacy
Jason W Skudlarek, Andrew J Cooke, Helen J Mitchell, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
ESMO Open
|
October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
S Morganti, R J Kusmick, M E Hughes, et al.
ESMO Open
|
November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆
A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open
|
August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
A Strahan, Q Jin, A S Raghavendra, et al.
Organic Letters
|
January 13, 2026
Asymmetric Synthesis of KRAS G12C Inhibitor MK-1084 via a Crystallization-Induced Diastereomer Transformation (CIDT)
Hongming Li, Gao Shang, Zhiguo J Song, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A G Waks, O Cohen, B Kochupurakkal, et al.
Journal of Medicinal Chemistry
|
March 23, 2021
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
Ryan V Quiroz, Michael H Reutershan, Sebastian E Schneider, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
A C Garrido-Castro, S E Kim, T Li, et al.
Organic Letters
|
October 30, 2025
Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19
Reed T Larson, Ben W H Turnbull, Patrick J Moon, et al.
Journal of Medicinal Chemistry
|
August 22, 2024
Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat <i>Acinetobacter baumannii</i>: From Screening Impurity to <i>In Vivo</i> Efficacy
Jason W Skudlarek, Andrew J Cooke, Helen J Mitchell, et al.
Page
of 7